Ikena Oncology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IKNA research report →
Companyikenaoncology.com
Ikena Oncology, Inc. , a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
- CEO
- Mark Manfredi
- IPO
- 2021
- Employees
- 10
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $718.82M
- P/E
- -1.35
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.20%
- ROIC
- -41.95%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-52,395,000 · -6.42%
- EPS
- $0.00 · 100.00%
- Op Income
- $-48,451,000
- FCF YoY
- -4.00%
Performance & Tape
- 52W High
- $23.28
- 52W Low
- $1.36
- 50D MA
- $15.75
- 200D MA
- $17.08
- Beta
- 0.50
- Avg Volume
- 18.00K
Get TickerSpark's AI analysis on IKNA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 4, 23 | ORBIMED ADVISORS LLC | other | 153,121 |
| Aug 4, 23 | ORBIMED ADVISORS LLC | other | 353,192 |
| Aug 4, 23 | Bonita David P | other | 153,121 |
| Aug 4, 23 | Bonita David P | other | 353,192 |
| Apr 15, 21 | Koehler Maria | other | 26,838 |
| Mar 30, 21 | Bonita David P | other | 5,429,023 |
| Mar 30, 21 | Bonita David P | buy | 375,000 |
| Mar 30, 21 | Bonita David P | other | 1,470,872 |
| Mar 30, 21 | Bonita David P | other | 157,288 |
| Mar 30, 21 | Bonita David P | buy | 48,400 |
Our IKNA Coverage
We haven't published any research on IKNA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IKNA Report →